J Claude Bennett Net Worth

The estimated Net Worth of J Claude Bennett is at least $663 Tysiąc dollars as of 4 September 2007. J Bennett owns over 20,000 units of Biocryst Pharmaceuticals stock worth over $662,693 and over the last 20 years J sold BCRX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

J Bennett BCRX stock SEC Form 4 insiders trading

J has made over 9 trades of the Biocryst Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently J exercised 20,000 units of BCRX stock worth $127,200 on 4 September 2007.

The largest trade J's ever made was buying 35,000 units of Biocryst Pharmaceuticals stock on 3 May 2006 worth over $227,500. On average, J trades about 8,444 units every 67 days since 2004. As of 4 September 2007 J still owns at least 85,730 units of Biocryst Pharmaceuticals stock.

You can see the complete history of J Bennett stock trades at the bottom of the page.

What's J Bennett's mailing address?

J's mailing address filed with the SEC is 2190 PARKWAY LAKE DR, , BIRMINGHAM, AL, 35244.

Insiders trading at Biocryst Pharmaceuticals

Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... oraz Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.

What does Biocryst Pharmaceuticals do?

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.

Complete history of J Bennett stock trades at Biocryst Pharmaceuticals

Biocryst Pharmaceuticals executives and stock owners

Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jon Stonehouse,
  President, Chief Executive Officer, Director
• Megan Sniecinski,
  Senior Vice President, Chief Business Officer
• Alane Barnes,
  Senior Vice President, Chief Legal Officer and Corporate Secretary
• Jon P. Stonehouse,
  CEO, Pres & Exec. Director
• Yarlagadda Babu,
  Senior Vice President - Drug Discovery
• William Sheridan,
  Senior Vice President, Chief Medical Officer
• Dr. William P. Sheridan,
  Chief Medical Officer & Sr. VP
• Dr. Yarlagadda S. Babu,
  Chief Discovery Officer
• Stephen Aselage,
  Independent Director
• Robert Ingram,
  Independent Chairman of the Board
• Kenneth Lee,
  Independent Director
• Nancy Hutson,
  Independent Director
• George Abercrombie,
  Independent Director
• Theresa Heggie,
  Independent Director
• Helen Thackray,
  Independent Director
• Dr. Helen M. Thackray FAAP, M.D.,
  Chief R&D Officer
• Anthony Doyle,
  Chief Financial Officer, Senior Vice President
• Alan Levin,
  Independent Director
• Charles Gayer,
  Senior Vice President, Chief Commercial Officer
• Allen Hodge,
  Vice President and General Manager for the United States
• Michael Jones,
  Executive Director - Finance, Principal Accounting Officer
• Alane P. Barnes,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Michael L. Jones,
  Exec. Director of Fin. & Principal Accounting Officer
• Dr. Elliott T. Berger,
  Sr. VP of Regulatory Affairs
• Robert C. Stoner,
  VP of HR
• John D. Bluth,
  Sr. VP of Investor Relations & Corp. Communications
• Anthony Doyle,
  Sr. VP & CFO
• Sanj K Patel,
  Director
• Stanley C Erck,
  Director
• Fred E Cohen,
  Director
• Lynne Powell,
  Senior VP - CCO
• Thomas R Ii Staab,
  Senior Vice President and CFO
• Bros. Advisors Lp Baker Bro...,
  
• John L Higgins,
  Director
• Felix Baker Bros. Investmen...,
  
• Zola P Horovitz,
  Director
• Robert S Lowrey,
  Controller, PAO
• Steven K Galson,
  Director
• Steve Aselage,
  Director
• Brothers Life Sciences Capi...,
  
• David Mc Cullough,
  VP
• Bros. Capital (Gp), Llcbake...,
  
• Stephen R Biggar,
  Director
• Stuart Grant,
  SR VP & CFO
• Beth C Seidenberg,
  Director
• William W Featheringill,
  Director
• / Tisch Capital (Gp), Llcba...,
  
• Biotech Capital (Gp), Llcba...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Mike Mills,
  Principal Accounting Officer
• Partners L P/Ilbiotechnolog...,
  
• Carl L Gordon,
  Director
• Charles E Bugg,
  CEO
• J Claude Bennett,
  President
• John A Montgomery,
  Director
• Jonathan M Nugent,
  VP Corp Communications
• W James Alexander,
  SR. VP, Chief Medical Officer
• Randall B Riggs,
  VP Business Development
• Michael A Darwin,
  CFO
• Randolph C Steer,
  Director
• Joseph H Jr Sherrill,
  Director
• William M Iii Spencer,
  Director
• Charles A Sanders,
  Director
• Peder Jensen,
  Director
• Amy E Mc Kee,
  Director
• Machelle Sanders,
  Director
• Vincent Milano,
  Director